



**Pfizer Limited**

The Capital, 1802 / 1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

September 7, 2018

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai - 400 001  
Scrip Code: 500680

The Manager, Listing Dept.  
The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
Scrip Symbol: PFIZER

Dear Sirs,

**Sub: Proceedings of the 67<sup>th</sup> Annual General Meeting – Pfizer Limited**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed proceedings of the 67<sup>th</sup> Annual General Meeting of the Company held on September 6, 2018.

We request you to kindly take the same on record.

Thanking you,

Yours truly,  
For Pfizer Limited

**Prajeet Nair**  
Company Secretary

Encl: A/a

**Fair Summary of Proceedings of the 67<sup>th</sup> Annual General Meeting of Pfizer Limited held on Thursday, September 6, 2018 at 3.00 p.m. at Rama Watumull Auditorium, Kishinchand Chellaram College, 124, Dinshaw Wachha Road, Churchgate, Mumbai-400 020.**

1. The 67<sup>th</sup> Annual General Meeting of the Members of Pfizer Limited was held on Thursday, September 6, 2018 at 3.00 p.m. at Rama Watumull Auditorium, Kishinchand Chellaram College, 124, Dinshaw Wachha Road, Churchgate, Mumbai-400 020.
2. The meeting was attended by all Directors, Company Secretary, Chief Financial Officer, representative of Auditors and Secretarial Auditor.
3. Mr. R. A. Shah took the Chair. The Company Secretary confirmed that the requisite quorum was present and the Chairman commenced the proceedings of the Meeting.
4. The Chairman then introduced all the members present on the dais and informed about proxies / representations received and registers available for inspection.
5. Mr. R. A. Shah then briefed the Shareholders from the Chairman's Statement.
6. Mr. S. Sridhar, Managing Director made a presentation to the Members giving an overview of the Pharmaceutical Industry and the Company's performance in 2017-18 and Market performance of the Company's key brands.
7. Dr. Anurita Majumdar, Executive Director – Medical made a presentation to the Members on Anti Microbial Resistance (AMR) and Pfizer's Commitment to fight against AMR.
8. With the consent of the Members present, the Notice convening the 67<sup>th</sup> Annual General Meeting, having been circulated to all the Members, was taken as read.
9. Since there was no qualification in the Independent Auditor's Report, the same was not required to be read and with the permission of the Members, the Independent Auditor's Report was taken as read.
10. The Chairman then took up the Agenda according to the Notice. He informed the Members that he and the Managing Director would be responding to the questions of the Members.
11. The Chairman stated that under the Companies Act, 2013, remote e-voting on the proposed resolutions contained in the notice of the Annual General Meeting was mandatory and the same had been provided by the Company. Mr. Bhumitra Dholakia, Designated Partner of Dholakia & Associates LLP, had been appointed Scrutinizer for conducting the remote e-voting and polling process in a fair and transparent manner.
12. The Chairman then put the following items on agenda for approval by poll.

**Ordinary Business:**

- i. To receive, consider and adopt the Audited Financial Statement of the Company for the financial year ended March 31, 2018, including the Reports of the Board of Directors and Auditors thereon.
- ii. To declare a dividend of Rs. 20.00 (200%) for the financial year ended March 31, 2018.
- iii. To appoint a Director in place of Dr. Anurita Majumdar (DIN: 05291758) who retires by rotation and being eligible, offers herself for re-appointment.
- iv. To ratify the appointment of Messrs. Walker Chandiook & Co. LLP, as Statutory Auditors of the Company.

**Special Business:**


- v. To consider and ratify the remuneration payable to Messrs. RA & Co., Cost Accountants for the financial year ending March 31, 2019.
- vi. To consider revision in the limit of maximum commission payable to Resident Indian Non-Executive Directors.
- vii. To consider continuation of the remaining term of Mr. R. A. Shah (DIN: 00009851) as an Independent Director, up to November 9, 2019.

13. The Shareholders were informed that the results of remote e-voting and poll conducted at the Annual General Meeting would be declared on or before September 8, 2018.

14. The Meeting was then concluded with a vote of thanks to the Chairman.

Thanking you,

Yours truly,  
For Pfizer Limited



Prajeet Nair  
Company Secretary

Place: Mumbai

Date: September 7, 2018